PNEUMOCOCCAL DISEASE

Pneumococcal disease causes significant morbidity and mortality across the globe, with an estimated 1.6 million deaths annually, mainly in lower-income countries.  A disproportionate number of these deaths are in children under the age of 5 years.  In the United States and Europe, Streptococcus pneumonia is the most common cause of community-acquired bacterial pneumonia in adults.

Featured Articles

No Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults
Kenneth J. Smith, Angela R. Wateska, Mary Patricia Nowalk, et al

The 13-valent pneumococcal conjugate vaccine (PCV13) is approved by the U.S. Food and Drug Administration for adults, but its role in older adults...

No Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
Lisa A. Jackson, Alejandra Gurtman, Kathryn Rice, et al

The currently recommended single dose of the 23-valent pneumococcal free polysaccharide vaccine (PPSV23) for adults 65 years of age and older does...

No Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older
Lisa A. Jackson, Alejandra Gurtman, Martin van Cleeff, et al

Unlike free polysaccharide vaccines, pneumococcal polysaccharide conjugate vaccines (PCVs) induce a T cell-dependent immune response and have the...

Yes Safety of 13-valent pneumococcal conjugate vaccine in infants and children: Meta-analysis of 13 clinical trials in 9 countries
Allison Thompson, Alejandra Gurtman, Scott Patterson, et al

Meta-analyses enable summarization and interpretation of data across clinical trials. When applied to safety data they allow for detection of rare...

No Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children
Hung Fu Tseng, Lina S. Sy, In-Lu Amy Liu, et al

Although no increased risk was detected for serious adverse events in the prelicensure trials for the 13-valent pneumococcal vaccine, Prevnar 13...

No Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults
Lisa A. Jackson, Alejandra Gurtman, Martin van Cleeff, et al

Streptococcus pneumoniae is a major cause of morbidity and mortality among adults 50 years of age and older in the United States....